ASCO GU 2017: Barriers in Progress in Muscle-Invasive and Non-muscle Invasive Bladder Cancer - Session Highlights

Orlando, Florida USA (UroToday.com) Maria De Santis, University of Warwick, discussed neoadjuvant chemotherapy (NAC). There is a 14% decreased risk of death associated with use of NAC and are included as recommended treatment in EAU/ASCO guidelines.

ASCO GU 2017: Keynote Lecture: Testicular Cancer - Session Highlights

Orlando, Florida USA (UroToday.com) In this keynote address, Dr. Lawrence H. Einhorn shared the wealth of his experience in treating testicular cancer. In the 1970s, contemporary treatment consisted of actinomycin-based therapy. The first cisplatin, vinblastine, bleomycin (PVB) study was reported in 1976, demonstrating complete remission in 33/47 patients (70%).

ASCO GU 2017: Year in Review: Penile Cancer - Session Highlights

Orlando, Florida USA (UroToday.com) According to Dr. Asif Muneer, penile cancer is a deadly disease. Therefore, misdiagnosis and undertreatment are major reasons for progression. In the United Kingdom, the number of cases increases over time.

ASCO GU 2017: Urothelial Carcinoma: Year in Review - Session Highlights

Orlando, Florida USA (UroToday.com) Matthew Milowsky, University of North Carolina, presented the year in review in bladder cancer. Immuno-oncology developments include the IMVigor, Checkmate and KEYNOTE are to name a few. Prior to 2016 there were no agents studied in cisplatin refractory disease. IMVigor 210 assessed use of atezolumab with overall response rate at 10% with 86% of complete response ongoing.

ASCO GU 2017: Keynote Lecture, Emerging Impact of Genomics on the Clinical Management of Bladder Cancer - Session Highlights

Orlando, Florida USA (UroToday.com) David McConkey, Johns Hopkins School of Medicine, gave the keynote lecture regarding genomics and bladder cancer. Genomics can inform diagnosis and prognostication. Collaborative efforts and completion of large-scale genomics projects have led to the most recent checkpoint blockade in advanced bladder cancer.

ASCO GU 2017: Optimizing Outcomes in Muscle-Invasive and Metastatic Bladder Cancer - Urologist View - Session Highlights

Orlando, Florida USA (UroToday.com) Eugene Lee, University of Kansas, discussed preoperative risk stratification. These include comorbidity indices with limitations including subjective nature and not uniform. The ‘eyeball’ test includes patient age, wheelchair sign, posture, skin/turgor and gait.

ASCO GU 2017: Optimizing Outcomes in Muscle-Invasive and Metastatic Bladder Cancer - Medical Oncologist’s Perspective - Session Highlights

Orlando, Florida USA (UroToday.com) Jonathan Rosenberg, Memorial Sloan Kettering, discussed chemotherapy. There is no role for carboplatin and cisplatin based regimens should be utilized. Pathological downstaging is associated with high cure rate with pT2 having overall survival in the Memorial Sloan series at 90% v37%, respectively.
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe